 Recently, a Phase I dose escalation study to evaluate maximum tolerated dose MTD of HIPEC administration of cisplatin in recurrent epithelial ovarian cancer EOC patients was published. The MTD of cisplatin was 100 milligrams per meter squared mgm2 with no mortality or safety concerns. While the trial had only 12 patients, all were able to receive post-operative IV chemotherapy, with all patients completing at least five cycles. 